Comparing domain interactions within antibody Fabs with kappa and lambda light chains

mAbs

Volumn 8, Issue 7, 2016, Pages 1276-1285

  Toughiri, Raheleh ^a,b   Wu, Xiufeng ^a   Ruiz, Diana ^a   Huang, Flora ^a   Crissman, John W ^a   Dickey, Mark ^a   Froning, Karen ^a   Conner, Elaine M ^a   Cujec, Thomas P ^a   Demarest, Stephen J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b SORRENTO THERAPEUTICS   (United States)

Author keywords

Antibody; Fab; kappa light chain; lambda light chain; stability

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; PERTUZUMAB; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; IMMUNOGLOBULIN G;

CIRCULAR DICHROISM; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; FLUORESCENT ANTIBODY TECHNIQUE; MAMMAL CELL; MOLECULAR CLONING; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN UNFOLDING; SECRETION (PROCESS); SIZE EXCLUSION CHROMATOGRAPHY; THERMOSTABILITY; CHEMISTRY; COMPARATIVE STUDY; HUMAN; PROTEIN DOMAIN;

HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; PROTEIN DOMAINS;

EID: 84987916552     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1214785     Document Type: Article

References (30)

1. D.M.Ecker, S.D.Jones, H.L.Levine. The therapeutic monoclonal antibody market. mAbs 2015; 7:9-14; PMID:25529996; http://dx.doi.org/10.4161/19420862.2015.989042
2. P.Bork, L.Holm, C.Sander. The immunoglobulin fold. Structural classification, sequence patterns and common core. J Mol Biol 1994; 242:309-20; PMID:7932691.
3. M.J.Feige, J.Buchner. Principles and engineering of antibody folding and assembly. Biochim Biophys Acta 2014; 1844:2024-31; PMID:24931831; http://dx.doi.org/10.1016/j.bbapap.2014.06.004
4. A.W.Vermeer, W.Norde. The thermal stability of immunoglobulin:unfolding and aggregation of a multi-domain protein. Biophys J 2000; 78:394-404; PMID:10620303; http://dx.doi.org/10.1016/S0006-3495(00)76602-1
5. E.Garber, S.J.Demarest. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun 2007; 355:751-7; PMID:17321501; http://dx.doi.org/10.1016/j.bbrc.2007.02.042
6. N.Harn, C.Allan, C.Oliver, C.R.Middaugh. Highly concentrated monoclonal antibody solutions:direct analysis of physical structure and thermal stability. J Pharm Sci 2007; 96:532-46; PMID:17083094; http://dx.doi.org/10.1002/jps.20753
7. S.J.Demarest, S.M.Glaser. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel 2008; 11:675-87; PMID:18729019
8. D.Rothlisberger, A.Honegger, A.Pluckthun. Domain interactions in the Fab fragment:a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol 2005; 347:773-89; PMID:15769469; http://dx.doi.org/10.1016/j.jmb.2005.01.053
9. J.F.Brandts, C.Q.Hu, L.N.Lin, M.T.Mos. A simple model for proteins with interacting domains. Applications to scanning calorimetry data. Biochemistry 1989; 28:8588-96; PMID:2690944; http://dx.doi.org/10.1021/bi00447a048
10. S.J.Demarest, G.Chen, B.E.Kimmel, D.Gustafson, J.Wu, J.Salbato, J.Poland, M.Elia, X.Tan, K.Wong, J.Short, G.Hansen. Engineering stability into Escherichia coli secreted Fabs leads to increased functional expression. Protein Eng Des Sel 2006; 19:325-36; http://dx.doi.org/10.1093/protein/gzl016
11. J.S.Michaelson, S.J.Demarest, B.Miller, A.Amatucci, W.B.Snyder, X.Wu, F.Huang, S.Phan, S.Gao, A.Doern, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. mAbs 2009; 1:128-41; PMID:20061822; http://dx.doi.org/10.4161/mabs.1.2.7631
12. R.Jefferis, I.Deverill, N.R.Ling, W.G.Reeves. Quantitation of human total IgG, kappa IgG and lambda IgG in serum using monoclonal antibodies. J Immunol Methods 1980; 39:355-62; PMID:6780626; http://dx.doi.org/10.1016/0022-1759(80)90235-5
13. T.Matsunaga, V.Tormanen. Evolution of antibody and T-cell receptor V genes–the antibody repertoire might have evolved abruptly. Dev Comp Immunol 1990; 14:1-8; PMID:2338149; http://dx.doi.org/10.1016/0145-305X(90)90002-V
14. M.C.Franklin, K.D.Carey, F.F.Vajdos, D.J.Leahy, A.M.de Vos, M.X.Sliwkowski. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317-28; PMID:15093539; http://dx.doi.org/10.1016/S1535-6108(04)00083-2
15. R.Pejchal, K.J.Doores, L.M.Walker, R.Khayat, P.S.Huang, S.K.Wang, R.L.Stanfield, J.P.Julien, A.Ramos, M.Crispin, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011; 334:1097-103; PMID:21998254; http://dx.doi.org/10.1126/science.1213256
16. L.Goo, Z.Jalalian-Lechak, B.A.Richardson, J.Overbaugh. A combination of broadly neutralizing HIV-1 monoclonal antibodies targeting distinct epitopes effectively neutralizes variants found in early infection. J Virol 2012; 86:10857-61; PMID:22837204; http://dx.doi.org/10.1128/JVI.01414-12
17. X.Wu, A.J.Sereno, F.Huang, K.Zhang, M.Batt, J.R.Fitchett, D.He, H.L.Rick, E.M.Conner, S.J.Demarest. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies. mAbs 2015; 7:364-76; PMID:25611120; http://dx.doi.org/10.1080/19420862.2015.1007826
18. S.J.Demarest, V.Frasca. Differential Scanning Calorimetry in the Biopharmaceutical Sciences, In Biophysical Characterization of Proteins in Developing Biopharmaceuticals (D.J.Houde, S.A.Berkowitz, Ed.) 2014; pp 287-306, Elsevier B.V.
19. M.J.Feige, S.Groscurth, M.Marcinowski, Y.Shimizu, H.Kessler, L.M.Hendershot, J.Buchner. An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol Cell 2009; 34:569-79; PMID:19524537; http://dx.doi.org/10.1016/j.molcel.2009.04.028
20. L.J.Holt, C.Herring, L.S.Jespers, B.P.Woolven, I.M.Tomlinson. Domain antibodies:proteins for therapy. Trends Biotechnol 2003; 21:484-90; PMID:14573361; http://dx.doi.org/10.1016/j.tibtech.2003.08.007
21. O.Y.Borbulevych, S.M.Santhanagopolan, M.Hossain, B.M.Baker. TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms. J Immunol 2011; 187:2453-63; http://dx.doi.org/10.4049/jimmunol.1101268
22. J.L.Chen, G.Stewart-Jones, G.Bossi, N.M.Lissin, L.Wooldridge, E.M.Choi, G.Held, P.R.Dunbar, R.M.Esnouf, M.Sami, et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med 2005; 201:1243-55; PMID:15837811; http://dx.doi.org/10.1084/jem.20042323
23. G.V.Semisotnov, N.A.Rodionova, O.I.Razgulyaev, V.N.Uversky, A.F.Gripas, R.I.Gilmanshin. Study of the “molten globule” intermediate state in protein folding by a hydrophobic fluorescent probe. Biopolymers 1991; 31:119-28; PMID:2025683; http://dx.doi.org/10.1002/bip.360310111
24. K.Kuwajima. The molten globule state of α-lactalbumin. FASEB J 1996; 10:102-9; PMID:8566530
25. M.Huang, B.C.Furie, B.Furie. Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody. J Biol Chem 2004; 279:14338-46; PMID:14722079; http://dx.doi.org/10.1074/jbc.M314011200
26. M.Chodorge, S.Zuger, C.Stirnimann, C.Briand, L.Jermutus, M.G.Grutter, R.R.Minter. A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency. Cell Death Differ 2012; 19:1187-95; PMID:22261618; http://dx.doi.org/10.1038/cdd.2011.208
27. N.Ponomarenko, S.D.Chatziefthimiou, I.Kurkova, Y.Mokrushina, Y.Mokrushina, A.Stepanova, I.Smirnov, M.Avakyan, T.Bobik, A.Mamedov, et al. Role of kappa–>lambda light-chain constant-domain switch in the structure and functionality of A17 reactibody. Acta Crystallogr D Biol Crystallogr 2014; 70:708-19; http://dx.doi.org/10.1107/S1399004713032446
28. S.M.Lewis, X.Wu, A.Pustilnik, A.Sereno, F.Huang, H.L.Rick, G.Guntas, A.Leaver-Fay, E.M.Smith, C.Ho, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol 2014; 32:191-8; PMID:24463572; http://dx.doi.org/10.1038/nbt.2797
29. B.R.Miller, S.J.Demarest, A.Lugovskoy, F.Huang, X.Wu, W.B.Snyder, L.J.Croner, N.Wang, A.Amatucci, J.S.Michaelson, S.M.Glaser. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 23:549-57; http://dx.doi.org/10.1093/protein/gzq028
30. J.K.Myers, C.N.Pace, J.M.Scholtz. Denaturant m values and heat capacity changes:relation to changes in accessible surface areas of protein unfolding. Protein Sci 1995; 4:2138-48; PMID:8535251; http://dx.doi.org/10.1002/pro.5560041020